HOME >> MEDICINE >> NEWS
Treatment response to Aricept® (donepezil hydrochloride) not predicted by Apolipoprotein E4 genotype or gender

WASHINGTON, D.C. 11 July, 2000 -- Aricept® (donepezil hydrochloride) demonstrated beneficial effects on cognition and global function over the course of one year in a double-blind, placebo-controlled, multinational study in patients with mild to moderate Alzheimer's disease (AD). In this study, treatment response was not predicted by Apolipoprotein E4 (ApoE4) genotype and/or gender, according to data presented today at the World Alzheimer Congress in Washington D.C.

ApoE is a lipoprotein that carries cholesterol in the blood. The exact role the ApoE4 allele plays in the pathogenesis of AD or in the memory decline of cognitively impaired elderly is unclear presently. Furthermore, much of the evidence concerning a correlation between ApoE4 copy number and the pathological features of AD (e.g. neuronal plaque density and the appearance of neurofibrillary tangles) is contradictory. It has been suggested that patients carrying an ApoE4 allele may have a more severe cholinergic deficit than those who do not.

"The reports of associations between ApoE4 genotype, gender and response to cholinesterase inhibitor therapy in AD patients are conflicting. In this recently completed study, a secondary analysis showed that the treatment response to ARICEPT®, a cholinesterase inhibitor, was not predicted by ApoE4 genotype and/or gender in patients with mild to moderate AD," says Hilkka Soininen, M.D., Ph.D., University of Kuopio, Kuopio, Finland.

This one-year multinational, double-blind, placebo-controlled study enrolled 286 patients with mild to moderate AD from 28 sites in five Northern European countries (Denmark, Finland, Norway, Sweden and The Netherlands). Patients were randomized to receive either ARICEPT® (n=142; 5 mg/day for 28 days, and then 10 mg/day) or placebo (n=144) for one year. The mean age of the patients enrolled in the study was 72.5 (range: 49-88 years).

Outcomes measures included evaluation of global function (the Gottf
'"/>

Contact: Celeste Torello, Pfizer Inc.
212-733-6471
Porter Novelli
10-Jul-2000


Page: 1 2

Related medicine news :

1. Treatment of cardiac lesions without anaesthesic
2. Treatment guidelines for kids with bipolar disorder published
3. University of Washington joins new Autism Treatment Network to provide better medical services
4. Treatment for brain tumor does not always follow recommendations
5. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
6. Treatment of ductal carcinoma in situ varies widely in United States
7. Treatment options expand for patients with neuropathic pain
8. Treatment interruption shows no benefit in drug-resistant HIV infection
9. Peanut Allergy: Major Advances in Treatment and Education
10. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
11. Treatment helped reduce dose of inhaled corticosteroids while maintaining asthma control

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... generation. Yisrayl makes an astounding statement when he says that the entire Bible ... Bible details the current times so plainly that anyone should be able to see ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/24/2017)... NJ (PRWEB) , ... February 24, 2017 , ... ... robust marketing services, which specializes in thought leadership , media relations, social ... campaigns and services that will be powered through Act-On, an intuitive marketing automation ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... once again hosted their Military Wedding Giveaway, with the winning couple announced on ... Farms with services generously donated from local vendors: A Matter of Taste, Ryan ...
(Date:2/23/2017)... Boston, MA (PRWEB) , ... February 23, 2017 ... ... Education and Department of Justice jointly issued a letter to withdraw ... in accordance with their gender identity. The guidance issued in May 2016 by ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  The particle counters market is projected ... USD 275.9 million in 2016, at a CAGR ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical ... and growth in manufacturing industries in emerging nations ... particle counters. On the other hand, technical limitations ...
(Date:2/23/2017)... 23, 2017 Visiomed, the French leader ... 1997, is changing the landscape of healthcare with ... with pro-active, custom-made solutions. Recognizing the rising demand ... affordable healthcare without walls, Visiomed has launched BewellConnect, ... with healthcare professionals that is empowering the lives ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
Breaking Medicine Technology:
Cached News: